Eli Lilly Reports the P-III (EMBER-3) Trial Results of Imlunestrant to Treat ER+/HER2- Advanced Breast Cancer
Shots:
- The P-III (EMBER-3) study assessed imlunestrant alone, imlunestrant + abemaciclib & SoC ET (fulvestrant or exemestane) in patients (n=874; 32% in 1L & 64% in 2L treatment post progression) with ER+/HER2- advanced breast cancer. P-III (EMBER-4) trial is also evaluating imlunestrant for ER+/HER2- EBC (n=~6,000)
- Imlunestrant vs SoC ET showed significantly improved PFS by 38% with mPFS of 5.5 vs 3.8mos. & ORR of 14% vs 8% in those with ESR1 mutations while mPFS was 5.6 vs 5.5mos. in all. Post-hoc analysis suggested lower CNS progression rates
- Combination vs imlunestrant alone improved PFS by 43% with mPFS of 9.4 vs 5.5mos. & ORR of 27% vs 12% in all (irrespective of ESR1 mutation). OS was immature, its evaluation continues
Ref: Eli Lilly | Image: Eli Lilly
Related News:- HAYA Therapeutics and Eli Lilly Partner to Discover Novel Regulatory Genome Targets for Obesity and Other Metabolic Conditions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
